Integra Therapeutics

Integra Therapeutics is a Spanish biotechnology company spun-out from the Pompeu Fabra University, specializing in CRISPR-based gene editing tools to accelerate the development of novel therapeutics. It uses its gene writing platform FiCAT, which addresses common concerns associated with gene therapy such as gene size, precision, and stability. The platform is applicable for both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapies. It also uses CRISPR-Cas9 proteins and PiggyBac transposase to precisely engineer and insert DNA, reducing off-target occurrences. 

The company considers its ability to write large messages into genomes using its tech to be its edge. As fo June 2022, it had not disclosed its target indications and intended to work together with its funding investors on its plans going forward. 

Key customers and partnerships

In March 2023, Integra partnered with Predictive Oncology to advance gene therapy. Through the partnership, the companies would collaborate to help Integra Therapeutics to enhance the way it develops therapeutics for cancer.

Funding and financials

It raised EUR 6 million (USD 6.3 million) in its last seed round , which closed in March 2022 and was led by AdBio Partners, Invivo Capital, and Takeda Ventures. The funds were earmarked to further develop Integra’s platform and technologies.